HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: High-density lipoprotein (HDL) cholesterol levels are a strong inverse predictor of cardiovascular events. However, it is not clear whether this association is maintained at very low levels of low-density lipoprotein (LDL) cholesterol. METHODS: A post hoc analysis of the recently completed Treating to New Targets (TNT) study assessed the predictive value of HDL cholesterol levels in 9770 patients. The primary outcome measure was the time to a first major cardiovascular event, defined as death from coronary heart disease, nonfatal non-procedure-related myocardial infarction, resuscitation after cardiac arrest, or fatal or nonfatal stroke. The predictive relationship between HDL cholesterol levels at the third month of treatment with statins and the time to the first major cardiovascular event was assessed in univariate and multivariate analyses and was also assessed for specific LDL cholesterol strata, including subjects with LDL cholesterol levels below 70 mg per deciliter (1.8 mmol per liter). RESULTS: The HDL cholesterol level in patients receiving statins was predictive of major cardiovascular events across the TNT study cohort, both when HDL cholesterol was considered as a continuous variable and when subjects were stratified according to quintiles of HDL cholesterol level. When the analysis was stratified according to LDL cholesterol level in patients receiving statins, the relationship between HDL cholesterol level and major cardiovascular events was of borderline significance (P=0.05). Even among study subjects with LDL cholesterol levels below 70 mg per deciliter, those in the highest quintile of HDL cholesterol level were at less risk for major cardiovascular events than those in the lowest quintile (P=0.03). CONCLUSIONS: In this post hoc analysis, HDL cholesterol levels were predictive of major cardiovascular events in patients treated with statins. This relationship was also observed among patients with LDL cholesterol levels below 70 mg per deciliter. (ClinicalTrials.gov number, NCT00327691 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent studies have shown that HDL cholesterol (HDL-C) levels under statin treatment remain an independent predictor of the risk of cardiovascular events in patients who have been treated with statins to lower LDL-C levels4”
From MicroRNA‐33 Deficiency Reduces the Progression of Atherosclerotic Plaque in ApoE −/− Mice (2012) · cites this paper as [4]
In the citing paper
“Despite such an effect, however, the elevated CV risk associated specifically with low HDL-C levels was only partially corrected by statin treatment in the Treatment to New Targets (TNT) trial.151”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [151]
In the citing paper
“Despite such an effect, however, the elevated CV risk associated specifically with low HDL-C levels was only partially corrected by statin treatment in the Treatment to New Targets (TNT) trial.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [292]
In the citing paper
“existing evidence suggests that improved HDL levels are closely associated with reduced cardiovascular risk, indicating the potential value of nurse-led DSME in preventing T2DM complications (22).”
From Impact of nurse-led self-management education on type 2 diabetes: a meta-analysis (2025) · cites this paper as [22]
In the citing paper
“existing evidence suggests that improved HDL levels are closely associated with reduced cardiovascular risk, indicating the potential value of nurse-led DSME in preventing T2DM complications (22).”
From Impact of nurse-led self-management education on type 2 diabetes: a meta-analysis (2025) · cites this paper as [22]
Citations
Cites
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Self-citationDowns, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
High density lipoprotein as a protective factor against coronary heart disease
Gordon, T., Castelli, W. P., Hjortland, M. C., Kannel, W. B., & Dawber, T. R. (1977) · The American Journal of Medicine · doi:10.1016/0002-9343(77)90874-9 · Cited by 5,059
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Self-citationPREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162
Research works printed but not linked: 2
- 1994, Lancet, 344, 1383
- 10.1001/jama.251.3.351 · DOI · Paper page
Cited by
Kernan, W. N., Ovbiagele, B., Black, H. R., Bravata, D. M., Chimowitz, M. I., Ezekowitz, M. D., Fang, M. C., Fisher, M., Furie, K. L., Heck, D. V., et al. (2014) · Stroke · doi:10.1161/str.0000000000000024 · Cited by 5,170
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Self-citationNiacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht108 · Cited by 1,955
Borén, J., Chapman, M. J., Krauss, R. M., Packard, C. J., Bentzon, J. F., Binder, C. J., Daemen, M. J., Demer, L. L., Hegele, R. A., Nicholls, S. J., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz962 · Cited by 1,601
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
Chapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227
Jellinger, P. S., Handelsman, Y., Rosenblit, P. D., Bloomgarden, Z. T., Fonseca, V. A., Garber, A. J., Grunberger, G., Guerin, C. K., Bell, D. S. H., Mechanick, J. I., et al. (2017) · Endocrine Practice · doi:10.4158/ep171764.appgl · Cited by 1,094
Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength?
Martín-Timón, I. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i4.444 · Cited by 976
Evacetrapib and cardiovascular outcomes in high-risk vascular disease
Lincoff, A. M., Nicholls, S. J., Riesmeyer, J. S., Barter, P. J., Brewer, H. B., Fox, K. A. A., Gibson, C. M., Granger, C., Menon, V., Montalescot, G., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609581 · Cited by 801
Self-citationGenest, J., McPherson, R., Frohlich, J., Anderson, T., Campbell, N., Carpentier, A., Couture, P., Dufour, R., Fodor, G., Francis, G. A., et al. (2009) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(09)70715-9 · Cited by 768
High-Density Lipoprotein Subfractions - What the Clinicians Need to Know
Pirillo, A., Norata, G. D., & Catapano, A. L. (2013) · Cardiology · doi:10.1159/000346463 · Cited by 748
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706
Rayner, K. J., Sheedy, F. J., Esau, C. C., Hussain, F. N., Temel, R. E., Parathath, S., van Gils, J. M., Rayner, A. J., Chang, A. N., Suarez, Y., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57275 · Cited by 690
(2014) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2013.10.013 · Cited by 609
JCS 2018 Guideline on Diagnosis and Treatment of Acute Coronary Syndrome
Kimura, K., Kimura, T., Ishihara, M., Nakagawa, Y., Nakao, K., Miyauchi, K., Sakamoto, T., Tsujita, K., Hagiwara, N., Miyazaki, S., et al. (2019) · Circulation Journal · doi:10.1253/circj.cj-19-0133 · Cited by 565
Anti-inflammatory therapies for cardiovascular disease
Ridker, P. M., & Luscher, T. F. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu203 · Cited by 550
HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis
Tall, A. R., Yvan-Charvet, L., Terasaka, N., Pagler, T., & Wang, N. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.03.001 · Cited by 540
Besler, C., Heinrich, K., Rohrer, L., Doerries, C., Riwanto, M., Shih, D. M., Chroni, A., Yonekawa, K., Stein, S., Schaefer, N., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci42946 · Cited by 535
Ito, F., Sono, Y., & Ito, T. (2019) · Antioxidants · doi:10.3390/antiox8030072 · Cited by 535
“Low serum HDL level is another major risk factor for coronary disease [112,113] and is predictive of cardiovascular events in statin-treated patients with low LDL-cholesterol levels [114].”
BackgroundJellinger, P. S., Smith, D. A., Mehta, A. E., Ganda, O., Handelsman, Y., Rodbard, H. W., Shepherd, M. D., & Seibel, J. A. (2012) · Endocrine Practice · doi:10.4158/ep.18.s1.1 · Cited by 533
Rosenson, R. S., Brewer, H. B., Chapman, M. J., Fazio, S., Hussain, M. M., Kontush, A., Krauss, R. M., Otvos, J. D., Remaley, A. T., & Schaefer, E. J. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.155333 · Cited by 511
Briel, M., Ferreira-Gonzalez, I., You, J. J., Karanicolas, P. J., Akl, E. A., Wu, P., Blechacz, B., Bassler, D., Wei, X., Sharman, A., et al. (2009) · BMJ · doi:10.1136/bmj.b92 · Cited by 491
“Large cohort studies have identified high density lipoprotein cholesterol as a strong, independent, inverse predictor of risk of coronary heart disease.”
BackgroundFruchart, J.-C., Sacks, F., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.10.002 · Cited by 463
Self-citationThe role of lipid metabolism in aging, lifespan regulation, and age‐related disease
Johnson, A. A., & Stolzing, A. (2019) · Aging Cell · doi:10.1111/acel.13048 · Cited by 449
“HDL cholesterol is also a predictor of major cardiovascular events in patients treated with statins (Barter et al., 2007).”
BackgroundKulik, A., Ruel, M., Jneid, H., Ferguson, T. B., Hiratzka, L. F., Ikonomidis, J. S., Lopez-Jimenez, F., McNallan, S. M., Patel, M., Roger, V. L., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000182 · Cited by 448
Sampson, U. K., Fazio, S., & Linton, M. F. (2012) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0219-7 · Cited by 439
Hypolipidemic, Antioxidant, and Antiinflammatory Activities of Microalgae Spirulina
Deng, R., & Chow, T. (2010) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00200.x · Cited by 435
HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells
Tabet, F., Vickers, K. C., Cuesta Torres, L. F., Wiese, C. B., Shoucri, B. M., Lambert, G., Catherinet, C., Prado-Lourenco, L., Levin, M. G., Thacker, S., et al. (2014) · Nature Communications · doi:10.1038/ncomms4292 · Cited by 428
Self-citationKraus, W. E., Bhapkar, M., Huffman, K. M., Pieper, C. F., Krupa Das, S., Redman, L. M., Villareal, D. T., Rochon, J., Roberts, S. B., Ravussin, E., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30151-2 · Cited by 407
Sorrentino, S. A., Besler, C., Rohrer, L., Meyer, M., Heinrich, K., Bahlmann, F. H., Mueller, M., Horváth, T., Doerries, C., Heinemann, M., et al. (2010) · Circulation · doi:10.1161/circulationaha.108.836346 · Cited by 402
Chemical composition and health effects of Tartary buckwheat
Zhu, F. (2016) · Food Chemistry · doi:10.1016/j.foodchem.2016.02.050 · Cited by 362
Grundy, S. M. (2013) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2013.10.001 · Cited by 347
Self-citationRiwanto, M., Rohrer, L., Roschitzki, B., Besler, C., Mocharla, P., Mueller, M., Perisa, D., Heinrich, K., Altwegg, L., von Eckardstein, A., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.108753 · Cited by 337
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
Palmer, S. C., Navaneethan, S. D., Craig, J. C., Johnson, D. W., Perkovic, V., Hegbrant, J., & Strippoli, G. F. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007784.pub2 · Cited by 331
The metabolism and anti-atherogenic properties of HDL
Rye, K.-A., Bursill, C. A., Lambert, G., Tabet, F., & Barter, P. J. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800034-jlr200 · Cited by 331
Self-citationCoronary Artery Disease: From Mechanism to Clinical Practice
Shao, C., Wang, J., Tian, J., & Tang, Y.-D. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-15-2517-9_1 · Cited by 319
Grundy, S. M., Arai, H., Barter, P., Bersot, T. P., Betteridge, D. J., Carmena, R., Cuevas, A., Davidson, M. H., Genest, J., Kesäniemi, Y. A., et al. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2013.12.005 · Cited by 327
Self-citationGalvani, S., Sanson, M., Blaho, V. A., Swendeman, S. L., Obinata, H., Conger, H., Dahlbäck, B., Kono, M., Proia, R. L., Smith, J. D., et al. (2015) · Science Signaling · doi:10.1126/scisignal.aaa2581 · Cited by 314
Feig, J. E., Rong, J. X., Shamir, R., Sanson, M., Vengrenyuk, Y., Liu, J., Rayner, K., Moore, K., Garabedian, M., & Fisher, E. A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016086108 · Cited by 313
The emerging role of HDL in glucose metabolism
Drew, B. G., Rye, K.-A., Duffy, S. J., Barter, P., & Kingwell, B. A. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.235 · Cited by 307
Self-citationCardioprotective functions of HDLs
Rye, K.-A., & Barter, P. J. (2014) · Journal of Lipid Research · doi:10.1194/jlr.r039297 · Cited by 299
Self-citationChapman, M. J., Le Goff, W., Guerin, M., & Kontush, A. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehp399 · Cited by 298
Lüscher, T. F., Landmesser, U., von Eckardstein, A., & Fogelman, A. M. (2014) · Circulation Research · doi:10.1161/circresaha.114.300935 · Cited by 291
Meyer, J. M., Davis, V. G., Goff, D. C., McEvoy, J. P., Nasrallah, H. A., Davis, S. M., Rosenheck, R. A., Daumit, G. L., Hsiao, J., Swartz, M. S., et al. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2007.12.487 · Cited by 286
“Hypertension and low levels of high density lipoprotein (HDL), the so-called “good” cholesterol, have long been recognized as predictors of CHD risk (Barter et al., 2007), but the NCEP metabolic syndrome definition provided clinicians a useful concept for understanding the association between…”
BackgroundWoodruffe, S., Neubeck, L., Clark, R. A., Gray, K., Ferry, C., Finan, J., Sanderson, S., & Briffa, T. G. (2015) · Heart, Lung and Circulation · doi:10.1016/j.hlc.2014.12.008 · Cited by 275
“Cholesterol/lipid management Lowering low-density lipoprotein (LDL) through medication reduces morbidity and mortality from CVD [43].”
BackgroundBruckert, E., Labreuche, J., & Amarenco, P. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.12.023 · Cited by 273
“[6] Barter P, Gotto AM, LaRosa JC, et al.”
BackgroundDavidson, M. H., Ballantyne, C. M., Jacobson, T. A., Bittner, V. A., Braun, L. T., Brown, A. S., Brown, W. V., Cromwell, W. C., Goldberg, R. B., McKenney, J. M., et al. (2011) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2011.07.005 · Cited by 262
Self-citationFruchart, J.-C., Sacks, F. M., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.046 · Cited by 260
Self-citationKones, R. (2011) · Drug Design, Development and Therapy · doi:10.2147/dddt.s14934 · Cited by 259
Cooney, M. T., Dudina, A., De Bacquer, D., Wilhelmsen, L., Sans, S., Menotti, A., De Backer, G., Jousilahti, P., Keil, U., Thomsen, T., et al. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.02.041 · Cited by 250
Ridker, P. M., Genest, J., Boekholdt, S. M., Libby, P., Gotto, A. M., Nordestgaard, B. G., Mora, S., MacFadyen, J. G., Glynn, R. J., & Kastelein, J. J. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60713-1 · Cited by 256
Self-citationAhmad, Z., Banerjee, P., Hamon, S., Chan, K.-C., Bouzelmat, A., Sasiela, W. J., Pordy, R., Mellis, S., Dansky, H., Gipe, D. A., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.039107 · Cited by 246
“…to the contrary, low HDL-C in this context might well predict lower risk because it correlates with lower non–HDL-C, LDL-C, and apolipoprotein B. 44 Along these lines, individuals with ANGPTL3 LOF mutations have panhypolipidemia with low HDL-C and have a lower risk of coronary arterial disease.”
Coronary heart disease risk: Low-density lipoprotein and beyond
Shaya, G. E., Leucker, T. M., Jones, S. R., Martin, S. S., & Toth, P. P. (2022) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2021.04.002 · Cited by 236
Lee, M., Saver, J. L., Towfighi, A., Chow, J., & Ovbiagele, B. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.04.020 · Cited by 240
“High triglyceride and low HDL cholesterol levels have been shown to singly and collectively boost the risk of cardiovascular events independent of conventional risk factors in large cohort studies [4–6].”
BackgroundMora, S., Glynn, R. J., & Ridker, P. M. (2013) · Circulation · doi:10.1161/circulationaha.113.002671 · Cited by 237
Bailey, D., Jahagirdar, R., Gordon, A., Hafiane, A., Campbell, S., Chatur, S., Wagner, G. S., Hansen, H. C., Chiacchia, F. S., Johansson, J., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.02.035 · Cited by 234
The Task Force on diabetes, P.-D. (2014) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114525548 · Cited by 236
Fruchart, J.-C. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.03.008 · Cited by 233
Self-citationLincoff, A. M., Tardif, J.-C., Schwartz, G. G., Nicholls, S. J., Rydén, L., Neal, B., Malmberg, K., Wedel, H., Buse, J. B., Henry, R. R., et al. (2014) · JAMA · doi:10.1001/jama.2014.3321 · Cited by 231
High-Density Lipoprotein and Coronary Heart Disease
Natarajan, P., Ray, K. K., & Cannon, C. P. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.01.008 · Cited by 230
Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk
Chapman, M. J., Redfern, J. S., McGovern, M. E., & Giral, P. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.01.008 · Cited by 227
Cardiovascular disease and periodontitis: an update on the associations and risk
Persson, G. R., & Persson, R. E. (2008) · Journal of Clinical Periodontology · doi:10.1111/j.1600-051x.2008.01281.x · Cited by 227
Novel Biological Functions of High-Density Lipoprotein Cholesterol
Mineo, C., & Shaul, P. W. (2012) · Circulation Research · doi:10.1161/circresaha.111.258673 · Cited by 227
Kosmas, C. E., Martinez, I., Sourlas, A., Bouza, K. V., Campos, F. N., Torres, V., Montan, P. D., & Guzman, E. (2018) · Drugs in Context · doi:10.7573/dic.212525 · Cited by 225
Lipid parameters for measuring risk of cardiovascular disease
Arsenault, B. J., Boekholdt, S. M., & Kastelein, J. J. P. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.223 · Cited by 225
“However, a number of new studies indicate that there is a residual risk of CVD associated with other markers of the lipoprotein–lipid profile, even in individuals with low LDL-cholesterol levels, or those who achieve low LDL-cholesterol levels on statin treatment”
BackgroundSelf-citationWaksman, R., Torguson, R., Kent, K. M., Pichard, A. D., Suddath, W. O., Satler, L. F., Martin, B. D., Perlman, T. J., Maltais, J.-A. B., Weissman, N. J., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.12.067 · Cited by 226
Rosenson, R. S., Brewer, H. B., Ansell, B., Barter, P., Chapman, M. J., Heinecke, J. W., Kontush, A., Tall, A. R., & Webb, N. R. (2013) · Circulation · doi:10.1161/circulationaha.113.000962 · Cited by 225
Self-citationHow Do Elevated Triglycerides and Low HDL-Cholesterol Affect Inflammation and Atherothrombosis?
Welty, F. K. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0400-4 · Cited by 221
Disorders of lipid metabolism. Clinical Guidelines 2023
Ezhov, M. V., Kukharchuk, V. V., Sergienko, I. V., Alieva, A. S., Antsiferov, M. B., Ansheles, A. A., Arabidze, G. G., Aronov, D. M., Arutyunov, G. P., Akhmedzhanov, N. M., et al. (2023) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2023-5471 · Cited by 219
MicroRNA‐33 Deficiency Reduces the Progression of Atherosclerotic Plaque in ApoE −/− Mice
Horie, T., Baba, O., Kuwabara, Y., Chujo, Y., Watanabe, S., Kinoshita, M., Horiguchi, M., Nakamura, T., Chonabayashi, K., Hishizawa, M., et al. (2012) · Journal of the American Heart Association · doi:10.1161/jaha.112.003376 · Cited by 220
Besler, C., Lüscher, T. F., & Landmesser, U. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201200224 · Cited by 219
Cholesterol transport system: An integrated cholesterol transport model involved in atherosclerosis
Yu, X.-H., Zhang, D.-W., Zheng, X.-L., & Tang, C.-K. (2019) · Progress in Lipid Research · doi:10.1016/j.plipres.2018.12.002 · Cited by 218
Lüscher, T. F., Taddei, S., Kaski, J.-C., Jukema, J. W., Kallend, D., Münzel, T., Kastelein, J. J. P., & Deanfield, J. E. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs019 · Cited by 217
Self-citationAtherosclerotic cardiovascular disease prevention in rheumatoid arthritis
Semb, A. G., Ikdahl, E., Wibetoe, G., Crowson, C., & Rollefstad, S. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0428-y · Cited by 214
High Density Lipoprotein Cholesterol and the Risk of All-Cause Mortality among U.S. Veterans
Bowe, B., Xie, Y., Xian, H., Balasubramanian, S., Zayed, M. A., & Al-Aly, Z. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00730116 · Cited by 213
Effects of Zinc supplementation on serum lipids: a systematic review and meta-analysis
Ranasinghe, P., Wathurapatha, W., Ishara, M., Jayawardana, R., Galappatthy, P., Katulanda, P., & Constantine, G. (2015) · Nutrition & Metabolism · doi:10.1186/s12986-015-0023-4 · Cited by 197
Boekholdt, S. M., Arsenault, B. J., Hovingh, G. K., Mora, S., Pedersen, T. R., LaRosa, J. C., Welch, K. M. A., Amarenco, P., DeMicco, D. A., Tonkin, A. M., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.002670 · Cited by 196
“Consistently, a TNT subanalysis has shown that the risk of cardiovascular events was lower among patients in the top versus bottom HDL-C quintile, at least among those assigned to atorvastatin 10 mg.(5) Among those assigned to aggressive lipidlowering with high-dose atorvastatin 80 mg (mean on-treatment LDL-C level 77…”
Self-citationDysfunctional High-Density Lipoprotein in Patients on Chronic Hemodialysis
Yamamoto, S., Yancey, P. G., Ikizler, T. A., Jerome, W. G., Kaseda, R., Cox, B., Bian, A., Shintani, A., Fogo, A. B., Linton, M. F., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.09.013 · Cited by 199
Rosenzweig, J. L., Ferrannini, E., Grundy, S. M., Haffner, S. M., Heine, R. J., Horton, E. S., & Kawamori, R. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0222 · Cited by 194
Self-citationESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.012 · Cited by 192
Sphingosine 1-phosphate levels in plasma and HDL are altered in coronary artery disease
Sattler, K. J. E., Elbasan, Ş., Keul, P., Elter-Schulz, M., Bode, C., Gräler, M. H., Bröcker-Preuss, M., Budde, T., Erbel, R., Heusch, G., et al. (2010) · Basic Research in Cardiology · doi:10.1007/s00395-010-0112-5 · Cited by 191
“The importance of HDL-C levels for cardiovascular risk [ 29 ], reverse cholesterol transport and ‘‘pleiotropic’’ HDL effects is well known [30].”
BackgroundHigh-density lipoprotein as a modulator of platelet and coagulation responses
van der Stoep, M., Korporaal, S. J. A., & Van Eck, M. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu137 · Cited by 191
Effects of Dietary Flavonoids on Reverse Cholesterol Transport, HDL Metabolism, and HDL function
Millar, C. L., Duclos, Q., & Blesso, C. N. (2017) · Advances in Nutrition · doi:10.3945/an.116.014050 · Cited by 192
Dyslipidemia and the Risk of Alzheimer’s Disease
Reitz, C. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0307-3 · Cited by 190
Canyelles, M., Tondo, M., Cedó, L., Farràs, M., Escolà-Gil, J. C., & Blanco-Vaca, F. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103228 · Cited by 188
Laboratory Assessment of HDL Heterogeneity and Function
Movva, R., & Rader, D. J. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2007.101923 · Cited by 188
Nicholls, S. J., Andrews, J., Kastelein, J. J. P., Merkely, B., Nissen, S. E., Ray, K. K., Schwartz, G. G., Worthley, S. G., Keyserling, C., Dasseux, J.-L., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.2121 · Cited by 185
Self-citationHigh-Density Lipoproteins: – Multifunctional but Vulnerable Protections from Atherosclerosis –
Annema, W., & von Eckardstein, A. (2013) · Circulation Journal · doi:10.1253/circj.cj-13-1025 · Cited by 183
Schwartz, G. G., Olsson, A. G., Ballantyne, C. M., Barter, P. J., Holme, I. M., Kallend, D., Leiter, L. A., Leitersdorf, E., McMurray, J. J. V., Shah, P. K., et al. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.09.017 · Cited by 183
Self-citationWaring, A. C., Rodondi, N., Harrison, S., Kanaya, A. M., Simonsick, E. M., Miljkovic, I., Satterfield, S., Newman, A. B., Bauer, D. C., & for the Health, A. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04328.x · Cited by 182
Effects of Statins on High-Density Lipoproteins: A Potential Contribution to Cardiovascular Benefit
McTaggart, F., & Jones, P. (2008) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-008-6113-z · Cited by 177
Mora, S., Wenger, N. K., DeMicco, D. A., Breazna, A., Boekholdt, S. M., Arsenault, B. J., Deedwania, P., Kastelein, J. J. P., & Waters, D. D. (2012) · Circulation · doi:10.1161/circulationaha.111.088591 · Cited by 177
Self-citationFenofibrate: A Review of its Use in Dyslipidaemia
McKeage, K., & Keating, G. M. (2011) · Drugs · doi:10.2165/11208090-000000000-00000 · Cited by 175
Sattler, K., & Levkau, B. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvp070 · Cited by 174
(2011) · American Heart Journal · doi:10.1016/j.ahj.2010.12.007 · Cited by 174
Nicholls, S. J., Puri, R., Ballantyne, C. M., Jukema, J. W., Kastelein, J. J. P., Koenig, W., Wright, R. S., Kallend, D., Wijngaard, P., Borgman, M., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.2112 · Cited by 174
Self-citation
Metadata
- Authors
- Barter, P., Gotto, A. M., LaRosa, J. C., Maroni, J., Szarek, M., Grundy, S. M., Kastelein, J. J. P., Bittner, V., & Fruchart, J.-C.
- Affiliations
- The Heart Research Institute (AU)
- Cornell University (US)
- SUNY Downstate Health Sciences University (US)
- Pfizer (United States) (US)
- The University of Texas Southwestern Medical Center (US)
- Amsterdam UMC Location University of Amsterdam (NL)
- University of Alabama (US)
- Institut Pasteur de Lille (FR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-09-27
- Volume
- 357
- Issue
- 13
- Pages
- 1301-1310
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2158057499
- Cited by
- 1,610
- References
- 24
- Citations by year
- 2026: 29 · 2025: 51 · 2024: 34 · 2023: 48 · 2022: 36 · 2021: 51 · 2020: 79 · 2019: 72 · 2018: 59 · 2017: 75 · 2016: 90 · 2015: 106 · 2014: 128 · 2013: 126 · 2012: 130
- FWCI
- 113.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- HDL cholesterol, LDL cholesterol, very low LDL cholesterol, major cardiovascular events, statin therapy, cardiovascular risk prediction, coronary artery disease, myocardial infarction, stroke, low HDL cholesterol
- MeSH terms
- Atorvastatin, Adult, Aged, Anticholesteremic Agents, Apolipoproteins, Cardiovascular Diseases, Coronary Disease, Double-Blind Method, Female, Heptanoic Acids, Humans, Hypercholesterolemia, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Pyrroles, Risk, Multivariate Analysis, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.